Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 198

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 198
---
 PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology
and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development.

In connection with Dr. Höfer’s appointment, the Company
entered into an employment agreement (the “Agreement”) with Dr. Höfer, which provides for her compensation
and other employment terms. Under the Agreement, Dr. Höfer will receive:

●A base salary of $300,000.00
per year;

●Participation in Equity-based
Compensation Plan of the Company, as determined at the discretion of the Company’s Compensation Committee; and

●Other customary benefits available
to executive officers of the Company.

There are no arrangements or understandings between Dr. Höfer
and any other person pursuant to which she was selected as an officer. Additionally, Dr. Höfer does not have any family relationships
with any director or executive officer of the Company. Further, Dr. Höfer has no related-party transactions reportable under Item
404(a) of Regulation S-K.

The Company issued a press release regarding Dr. Höfer’s
appointment, which is attached as Exhibit 99.1 to the Company’s March 25, 2025 Form 8-K and is incorporated herein
by reference.

Committees of the Board of Directors 

Upon the consummation of the Business Combination, the Company Board
reconstituted its audit committee, compensation committee and corporate governance and nomination committee. The Board of Directors adopted
a new charter for each of these committees, which comply with the applicable requirements of current SEC and Nasdaq rules. The Company
intends to comply with future requirements to the extent applicable. The Company Board may from time to time establish other committees.

98

Audit Committee 

As of the completion of the Business Combination, the members of our
audit committee consist of Mr. Jee, Mr. Lee and Mr. Park, with Mr. Park serving as the chairperson of this audit committee.
The composition of the Company’s audit committee will meet the requirements for independence under the current Nasdaq listing standards
and SEC rules and regulations. Each member of the audit committee is financially literate and the “audit committee financial expert”
as defined in Item 407(d)(5)(ii) of Regulation S-K will be Mr. Park. This designation does not impose on
Mr. Park any duties, obligations